Welcome to our dedicated page for Chiron Real Estate news (Ticker: XRN), a resource for investors and traders seeking the latest updates and insights on Chiron Real Estate stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chiron Real Estate's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chiron Real Estate's position in the market.
Chiron Real Estate (NYSE: XRN) will release first quarter 2026 financial results after market close on Wednesday, May 6, 2026, and will host a conference call and webcast on Thursday, May 7, 2026 at 9:00 a.m. ET.
Company executives Mark Decker Jr., Robert Kiernan, Alfonzo Leon and Danica Holley will host the call; a replay and archived webcast will be available through May 21, 2026.
Aditxt (Nasdaq: ADTX) announced Jeff Busch as CEO of its newly acquired subsidiary Ignite Proteomics on March 19, 2026. Ignite operates a commercial-stage precision oncology platform that measures active proteins to guide cancer therapy selection and has Medicare reimbursement.
Busch, founder and former CEO of Chiron Real Estate (NYSE: XRN), will lead commercial expansion and evaluate strategic growth and financing alternatives to scale revenue and pursue sustainable profitability.
Chiron Real Estate (NYSE: XRN) reported Q4 2025 results and 2026 guidance. Q4 net loss was $7.4M (loss of $0.55/share); Q4 FFO was $0.97/share (+26% YoY) and Core FFO was $1.16/share (+6.4% YoY). Same-property Cash NOI grew 5.4% and year-end occupancy was 96.0%.
Balance sheet: consolidated debt $653.9M, leverage 44.4%, weighted-average interest rate 3.74%. Capital moves: repurchased 175,634 shares for $6.0M, issued Series B preferred for $51.3M. Board moved common dividends to monthly at an unchanged annualized rate of $3.00 ($0.25/month Apr–Jun). 2026 Core FFO guidance: $4.30–$4.45.